CAS: 96156-26-2

Displurigen is an inhibitor of ATPase activity of HSP70.

Displurigen is an advanced immunotherapy agent, engineered from recombinant DNA technology, which is derived from a specifically modified microbial source to act as an immune modulator. By targeting specific receptors on immune cells, it enhances the adaptive immune response, thereby facilitating a robust and sustained activation of T-cells and B-cells. This targeted action leads to improved antigen presentation and subsequent effector function. Displurigen is primarily used in the context of investigating immune system disorders and developing treatments for autoimmune diseases and certain types of cancer. Its applications extend to preclinical and clinical research settings where precise modulation of the immune response is critical. Through its action, Displurigen offers potential in both understanding immune mechanisms and in the development of therapeutic interventions that necessitate fine-tuned immune activation or suppression.